In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Complix NV

www.complix.be

Latest From Complix NV

Appointments: Promethera, HealthTell, Baxter, Alzheon, Gilead, Arena and Ligand

This week's appointment roundup includes senior appointments by Promethera, HealthTell, Alzheon and Gilead Nordic with Baxter International, Therachon and Arena Pharmaceuticals making board appointments.

Appointments

Bioqube Takes The Reins At J&J Innovation's JLINX

The recently launched venture capital firm has partnered with J&J Innovation to manage its new European life sciences incubator. START-UP speaks with bioqube's managing partner Nico Vandervelpen.

BioPharmaceutical Europe

Deal Watch: Big Pharmas Lead Hectic New Year Deal-Making Pace

J&J Innovation's spate of deals led a busy week of deal-making involving many big pharmas. Sanofi exited its inhaled insulin partnership with MannKind, Merck collaborated with Quartet and Complix, Roche partnered with and helped finance C4, and Pfizer signed an immuno-oncology combo trial agreement with Syndax.

BioPharmaceutical Deals

Complix NV

Complix NV aims to construct therapeutic proteins that can bind to molecular targets no antibody has ever been able to reach, and that small molecules cannot fully inhibit. Its Alphabodies are structurally distinct from antibodies and from most other scaffolds – they can be designed to penetrate cell membranes, to remain stable inside cells, and to bind intracellular targets.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Complix NV
  • Senior Management
  • Mark Vaeck, PhD, CEO
    Yvonne McGrath , PhD, CSO
  • Contact Info
  • Complix NV
    Phone: (32) 9 261 69 40
    Agoralaan building A-bis
    BioVille
    Diepenbeek, 3590
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register